Charles River Laboratories International (NYSE:CRL) Sets New 1-Year Low – Time to Sell?

Charles River Laboratories International, Inc. (NYSE:CRL)’s stock price hit a new 52-week low during mid-day trading on Wednesday . The company traded as low as $159.65 and last traded at $162.66, with a volume of 49248 shares traded. The stock had previously closed at $163.64.

Analysts Set New Price Targets

Several research firms recently issued reports on CRL. Redburn Atlantic began coverage on shares of Charles River Laboratories International in a research report on Monday, October 14th. They issued a “sell” rating and a $151.00 target price on the stock. Evercore ISI lifted their price objective on Charles River Laboratories International from $190.00 to $225.00 and gave the company an “in-line” rating in a research note on Thursday, November 7th. William Blair downgraded shares of Charles River Laboratories International from an “outperform” rating to a “market perform” rating in a research report on Wednesday, January 22nd. TD Cowen boosted their price objective on shares of Charles River Laboratories International from $203.00 to $227.00 and gave the stock a “hold” rating in a research note on Monday, November 11th. Finally, CLSA lowered shares of Charles River Laboratories International from a “hold” rating to an “underperform” rating and set a $164.00 target price on the stock. in a report on Monday, November 18th. Three equities research analysts have rated the stock with a sell rating, thirteen have assigned a hold rating and one has given a buy rating to the stock. According to data from MarketBeat.com, the company currently has a consensus rating of “Hold” and an average price target of $204.38.

Charles River Laboratories International Trading Down 1.2 %

The company has a debt-to-equity ratio of 0.61, a quick ratio of 1.14 and a current ratio of 1.48. The business’s 50 day moving average price is $185.87 and its 200-day moving average price is $196.49. The firm has a market cap of $8.27 billion, a price-to-earnings ratio of 20.28, a price-to-earnings-growth ratio of 5.94 and a beta of 1.38.

Charles River Laboratories International (NYSE:CRL) last released its earnings results on Wednesday, November 6th. The medical research company reported $2.59 EPS for the quarter, topping analysts’ consensus estimates of $2.43 by $0.16. Charles River Laboratories International had a return on equity of 14.29% and a net margin of 10.44%. The company had revenue of $1.01 billion for the quarter, compared to the consensus estimate of $975.99 million. During the same quarter last year, the business posted $2.72 EPS. Charles River Laboratories International’s quarterly revenue was down 1.6% compared to the same quarter last year. Equities analysts expect that Charles River Laboratories International, Inc. will post 10.18 EPS for the current year.

Insider Activity

In other Charles River Laboratories International news, Director Richard F. Wallman sold 6,621 shares of the firm’s stock in a transaction that occurred on Thursday, November 7th. The shares were sold at an average price of $216.12, for a total value of $1,430,930.52. Following the sale, the director now owns 12,386 shares in the company, valued at approximately $2,676,862.32. This trade represents a 34.83 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Corporate insiders own 1.30% of the company’s stock.

Institutional Trading of Charles River Laboratories International

Hedge funds have recently added to or reduced their stakes in the business. Wolff Wiese Magana LLC bought a new position in Charles River Laboratories International during the third quarter valued at about $32,000. Versant Capital Management Inc increased its holdings in shares of Charles River Laboratories International by 1,071.4% in the 4th quarter. Versant Capital Management Inc now owns 164 shares of the medical research company’s stock valued at $30,000 after purchasing an additional 150 shares during the period. Assetmark Inc. boosted its stake in shares of Charles River Laboratories International by 1,153.3% during the 3rd quarter. Assetmark Inc. now owns 188 shares of the medical research company’s stock valued at $37,000 after buying an additional 173 shares during the period. Pinnacle Bancorp Inc. grew its stake in Charles River Laboratories International by 52.0% in the fourth quarter. Pinnacle Bancorp Inc. now owns 190 shares of the medical research company’s stock valued at $35,000 after purchasing an additional 65 shares in the last quarter. Finally, Wilmington Savings Fund Society FSB bought a new position in Charles River Laboratories International during the third quarter valued at approximately $59,000. Institutional investors own 98.91% of the company’s stock.

Charles River Laboratories International Company Profile

Charles River Laboratories International, Inc provides drug discovery, non-clinical development, and safety testing services in the United States, Europe, Canada, the Asia Pacific, and internationally. It operates through three segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Solutions (Manufacturing).